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Abstract
Background: Previously we have shown that Ag85B-TB10.4 is a highly efficient vaccine against tuberculosis when delivered
in a Th1 inducing adjuvant based on cationic liposomes. Another Th1 inducing adjuvant, which has shown a very promising
profile in both preclinical and clinical trials, is IC31H. In this study, we examined the potential of Ag85B-TB10.4 delivered in
the adjuvant IC31H for the ability to induce protection against infection with Mycobacterium tuberculosis. In addition, we
examined if the antigen dose could influence the phenotype of the induced T cells.
Methods and Findings: We found that vaccination with the combination of Ag85B-TB10.4 and IC31H resulted in high
numbers of polyfunctional CD4 T cells co-expressing IL-2, IFN-c and TNF-a. This correlated with protection against
subsequent challenge with M.tb in the mouse TB model. Importantly, our results also showed that both the vaccine induced
T cell response, and the protective efficacy, was highly dependent on the antigen dose. Thus, whereas antigen doses of 5
and 15 mg did not induce significant protection against M.tb, reducing the dose to 0.5 mg selectively increased the number
of polyfunctional T cells and induced a strong protection against infection with M.tb. The influence of antigen dose was also
observed in the guinea pig model of aerosol infection with M.tb. In this model a 2.5 fold increase in the antigen dose
reduced the protection against infection with M.tb to the level observed in non-vaccinated animals.
Conclusions/Significance: Small changes in the antigen dose can greatly influence the induction of specific T cell
subpopulations and the dose is therefore a crucial factor when testing new vaccines. However, the adjuvant IC31H can, with
the optimal dose of Ag85B-TB10.4, induce strong protection against Mycobacterium tuberculosis. This vaccine has now
entered clinical trials.
Citation: Aagaard C, Hoang TTKT, Izzo A, Billeskov R, Troudt J, et al. (2009) Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31H against
Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose. PLoS ONE 4(6): e5930. doi:10.1371/journal.pone.0005930
Editor: Delia Goletti, National Institute for Infectious Diseases (INMI) L. Spallanzani, Italy
Received February 25, 2009; Accepted May 5, 2009; Published June 16, 2009
Copyright:  2009 Aagaard et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for studies at Colorado State University was provided by NIH, NIAID, grant NO1-AI-40091. This work was supported by Aeras Global TB vaccine
foundation and the ongoing clinical development of the H4/IC31 vaccine is done in partnership with Sanofi Aventis supported by Aeras global vaccine
foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: JDI@ssi.dk
. These authors contributed equally to this work.
Introduction
The global effort to develop an effective TB vaccine involves
different strategies including live attenuated vaccines [1], virally
vectored TB vaccines [2], and subunit vaccines [3,4]. The subunit
approach holds a number of advantages, such as increased safety and
s t a b i l i t ya sw e l la st h ed e m o n s t r a t e da b i l i t yt ob o o s tp r i o rB C G
immunization [5,6]. In addition, as subunit vaccines does not appear
to be influenced by environmental mycobacteria this type of vaccine
may be of particular use in the developing world [7]. However,
progress in this field has been delayed by the lack of available
adjuvants that induce a strong cell-mediated immune (CMI)
response. Recently we showed that Ag85B-TB10.4 delivered in
cationic dimethyldioctadecylammonium (DDA) and Monopho-
sphoryl Lipid A (MPL) induced a strong protection against infection
with M.tb [8]. Furthermore, the closely related vaccine Ag85B-
ESAT-6 delivered in the CAF-01 adjuvant (consisting of DDA and
trehalose 6,69-dibehenate (TDB)) or in IC31H adjuvant induced a
strong Th1 response that efficiently protected against infection with
M.tb [9,10]. The IC31H adjuvant consists of a vehicle based on the
cationic peptide KLKL5KLK and the immunostimulatory oligo-
deoxynucleotide ODN1a that signals through the TLR9 receptor.
The combination of Ag85B-TB10.4 and IC31H is attractive for
several reasons; 1) IC31H has been shown to promote a strong Th1
response and was demonstrated to have a very compelling safety
profile in the first clinical trial, and 2) Ag85B-TB10.4 has the
advantage that it does not include ESAT-6, which is a valuable
diagnostic reagent and the basis of a number of commercial
diagnostic tests [11–13]. In the present work we therefore examined
the combination of Ag85B-TB10.4 and IC31H for immunogenicity
and efficacyagainst infectionwith M.tb.OurresultsshowthatAg85B-
TB10.4/IC31H can induce high numbers of polyfunctional CD4 T
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5930cells and induce efficient protection against infection with M.tb.
However, the combination of the immunogenic Ag85B-TB10.4
antigen and the IC31H adjuvant activity was very sensitive to the dose
of antigen. Thus, whereas the higher doses antigen of Ag85B-TB10.4
(5 and 15 mg) in IC31H, induced very modest immune responses that
did not protect against M.tb challenge, reducing the dose to 0.5 mg
Ag85B-TB10.4 in IC31H led to a selective increase in the numbers of
polyfunctional T cells, which in turn increased the protection against
M.tb to the same level as BCG. Also in the Guinea pig TB animal
model we observed a strong correlation between vaccine efficacy and
antigen dose. Thus, we found that decreasing or increasing the
antigen dose as little as 2.5 fold compared to the optimal dose led to a
significantly reduced protective efficacy of the vaccine.
Results
Immune responses induced by Ag85B-TB10.4 in IC31H
using different vaccination doses
We first analyzed the immunogenicity of different doses of
Ag85B-TB10.4 delivered in IC31H and whether both components
of the fusion protein were recognized by the immune system after
immunization. Groups of mice were vaccinated three times with
Ag85B-TB10.4 in the adjuvant IC31H. As a negative control, a
group of mice received the adjuvant alone (data not shown). The
antigen dose used in the experiment was in the range from 0.005
to 15 mg. One week after the last injection, the mice were bled,
and the IFN-c release was evaluated after in vitro stimulation of
purified PBMCs with Ag85B or TB10.4 (or ESAT-6 as a negative
control) (Fig. 1A). Vaccination with Ag85B-TB10.4/IC31H
promoted a strong T cell response characterized by an IFN-c in
vitro recall response upon stimulation with Ag85B or TB10.4.
However, the immune response promoted by the vaccine was
greatly influenced by the dose of the antigen. The highest
immune-response was induced by vaccination with 1 mg
(.20000 pg IFN-c/ml) and increasing the dose from 1 to 5 mg
(or 15 mg) strongly reduced the secretion of IFN-c following in
vitro stimulation with Ag85B or TB10.4 (compared to mice
vaccinated with 0.5 mg antigen, p,0.001). The influence of dose
was particularly apparent when using the 15 mg dose which
resulted in a very low IFN-c response (362+/2305 pg/ml IFN-c
Figure 1. Immune recognition of vaccination antigens. PBMC’s (A) or splenocytes (B) isolated from groups of mice vaccinated with different
doses of Ag85B-TB10.4 in IC31H (and a saline control group) were stimulated with either Ag85B or TB10.4 (or ESAT-6 as negative control). After
72 hours the concentration of cell released IFN-c was determined by ELISA. Five mice per group were pooled. Values represent the means of triplicate
and SEM’s are indicated.
doi:10.1371/journal.pone.0005930.g001
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after in vitro stimulation with TB10.4) that did not differ
significantly from that observed in non-vaccinated mice (data
not shown), or vaccinated mice stimulated in vitro with control
antigen ESAT-6. Remarkably, even a low dose of 0.005 mg
Ag85B-TB10.4 still induced a significant immune response
(8292+/22324 and 618+/2382 pg/ml IFN-c after in vitro
stimulation with Ag85B or TB10.4 respectively, Fig. 1A). The
same dose dependency was observed when analyzing splenocytes
(Fig. 1B) where the optimal dose once more seemed to peak
around 0.5 mg Ag85B-TB10.4. When comparing the secretion of
IFN-c with the number of antigen specific cells (here shown by
ELISPOT using Ag85B for in vitro stimulation of splenocytes)
following immunization with Ag85B-TB10.4 there was a clear
correlation. Thus, immunization with 0.5 mg induced the highest
number of antigen specific cells measured by the ELISPOT assay
and increasing the dose 10-fold led to a dramatic decrease in the
number of Ag85B specific T cells, demonstrating that the
increased secretion of IFN-c in animals immunized with 0.5 mg
compared to 5 (or 15) mg, was in part due to an increase in the
number of antigen specific T cells (Fig. 2).
Vaccination with Ag85B-TB10.4 in IC31H induces
polyfunctional CD4 T cells
We next analyzed the cytokine expression of the T cells induced
by immunizing with 0.5 mg compared to 5 mg Ag85B-TB10.4/
IC31H. In particular, we were interested in analyzing the induction
of polyfunctional CD4 T cells as these have been shown to
correlate with protective immunity against infections such as
Leishmania major and to form the basis for a long lived memory
response [14,15]. PBMCs from vaccinated mice were stimulated in
vitro with Ag85B, TB10.4 or Ag85B-TB10.4 and analyzed by flow
cytometry for expression of CD4, CD8, IFN-c, TNF-a, and IL-2.
The results showed that immunizing with Ag85B-TB10.4/IC31H
induced two major polyfunctional T cell populations; CD4
+IFN-
c
+IL-2
+TNF-a
+ and CD4
+IL-2
+TNF-a
+ T cells. Similarly to in
the result depicted in figure 1, we observed an increased response
in the group vaccinated with 0.5 mg Ag85B-TB10.4 compared to
the group vaccinated with 5 mg Ag85B-TB10.4, against both
antigen components (Fig. 3). Interestingly, the T cell subsets that
were expanded by decreasing the antigen dose from 5 mgt o
0.5 mg, were the polyfunctional memory T cell subsets expressing
IFN-c/IL-2/TNF-a (Fig. 3B–D) and this was observed for both
Ag85B (2 fold increase in IFN-c/IL-2/TNF-a cells) and TB10.4
(up to 10 fold increase in IFN-c/IL-2/TNF-a cells) specific T cells
(Fig. 3B and C). We also compared the level of IFN-c production
in all the IFN-c expressing subpopulations from both vaccine
groups by looking at the mean fluorescence intensity (MFI). These
results showed that animals vaccinated with 0.5 mg Ag85B-TB10.4
produced significantly more IFN-c per cell, than the correspond-
ing subpopulation in animals vaccinated with the high dose (5 mg
Ag85B-TB10.4). This was observed for both Ag85B and TB10.4
specific T cells (Fig. 3E). In summary, vaccination with Ag85B-
TB10.4/IC31H induced polyfunctional CD4 T cells and reducing
the dose increased the immunogenicity of the vaccine, specifically
in terms of the proportion of polyfunctional T cells within the pool
of antigen specific T cells. Moreover, the T cells from animals
vaccinated with the low dose also produced more IFN-c per cell.
Thus, the observed increase in IFN-c production (Fig. 1 and 2) was
due to both an increase in T cells numbers and an increase in IFN-
c production by these T cells (Fig. 3).
Protective efficacy of Ag85B-TB10.4/IC31H in a mouse TB
infection model
We next examined the protective efficacy of different doses of
Ag85B-TB10.4/IC31H. Mice were vaccinated three times at two
weeks interval with Ag85B-TB10.4/IC31H and as a positive
control for protection, BCG vaccinated mice were included. Ten
weeks after the first vaccination, the mice were challenged by the
aerosol route with virulent M. tuberculosis and bacterial numbers
were assessed in the lungs six weeks post challenge. As observed
with the immunogenicity of the vaccine, the protective efficacy of
the vaccine also decreased when vaccination dose was increased
from 0.5 mg to 5 or 15 mg (Fig. 4, which show the result of two
independent experiments). Thus, mice vaccinated with 0.5 mg
Ag85B-TB10.4 in IC31H were found to have 5.0+/20.2 Log10
CFU in the lungs, which was not significantly different from that
observed in BCG vaccinated mice (4.90+/20.35 Log10 CFU), but
significantly reduced (p,0.001) compared to the bacterial
numbers in non-vaccinated mice (5.83+/20.12 Log10 CFU)
Figure 2. ELISPOT analysis of splenocytes from vaccinated animals. (A and B) Splenocytes isolated from groups of mice vaccinated with 3
different doses of Ag85B-TB10.4 in IC31H or a saline control group (Non Vacc.) were stimulated in vitro with Ag85B for 48 hours and subjected to
ELISPOT analysis (A) or stimulated for 72 hours to measure IFN-c cytokine secretion by ELISA (B). The bars represent means of 3 individual mice. SEMs
are indicated. In both (A) and (B) a vaccination dose of 0.5 mg Ag85B-TB10.4 gave significantly (*p,0.05, one-way ANOVA and Tukey’s post test)
higher antigen responses, compared to vaccination doses of 5 and 15 mg.
doi:10.1371/journal.pone.0005930.g002
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of Ag85B-TB10.4 in IC31H, in which the bacterial numbers were
not significantly different from that found in the lungs of non-
vaccinated mice (Fig. 4A). Repeating the experiment led to the
same conclusion although the overall bacterial numbers were
slightly lower in all the groups (Fig. 4B).
In conclusion, the ability of the vaccine, Ag85B-TB10.4/IC31H,
to induce protection against M.tb correlated with the quantity and
quality of the T cell response induced, and in particular with the
proportion of polyfunctional T cells that co-express all three
cytokines,which washighestwhen the lowestantigen dosewasused.
Protective efficacy of Ag85B-TB10.4/IC31H in a guinea pig
TB infection model
Having shown that the mouse model was very sensitive to the
dose of antigen used for vaccination, we next examined the
protective efficacy of Ag85B-TB10.4/IC31H in the guinea pig TB
model, and whether a dose dependency would also be observed in
this model. Groups of 15 animals per group were vaccinated three
times with Ag85B-TB10.4 in IC31H or with IC31H alone (as a
negative control) usinganantigendose of 0.1,1.0,10,20 and50 mg.
10 weeks after the last vaccination the animals were infected via the
aerosol route with virulent M. tuberculosis, and survival was
monitored (based on weight loss). The results showed that there
was no significant difference in survival between adjuvant treated
guinea pigs and those receiving 0.1 or 50 mg of vaccine (Fig. 5).
However, significant differences (log rank analysis) in survival from
that of adjuvant treated animals were observed with doses of 1, 10
(p,0.05) and 20 mg( p ,0.005). Taken together, the data suggest
that there is a range of doses of Ag85B-TB10.4 (in IC31H) that can
be used tosignificantlyprolongthe survivalofguineapigs,outsideof
which, above and below, the vaccine becomes ineffective, and that
the guinea pig model is sensitive enough to distinguish these
differences. Thus, as observed in the mouse TB model, there was a
strict dose dependency regarding the antigen Ag85B-TB10.4, but
the optimal dose of Ag85B-TB10.4 also induced significant
protection in the guinea pig TB model.
Discussion
Our study demonstrates that Ag85B-TB10.4 administered in
the novel adjuvant IC31H promote an immune response that
efficiently protects against aerosol infection with M.tb. Surprising-
Figure 3. Ag85B and TB10.4 specific T cells are polyfunctional. (A). Cytokine profiles of H4 specific CD4 T cells were determined by first dividing
the CD4 T cells into IFN-c positive (+)o rI F N - c negative (-) cells. Both the IFN-c
+ and IFN-c
2 cells were analyzed with respect to the production of TNF-a
andIL-2.Thenumbers in thequadrant gatesof theplots denominateseach distinct populationbasedontheir cytokineproduction andis colorcodedas
shown. (B–D) The pie charts are grouped after vaccination dose and colour coded according to the cytokine production profile and summarizes the
fractions of the CD4
+ T cell response (out of the antigen specific CD4 T cells) that are positive for a given cytokine production profile. Every possible
combination of cytokines is shown on the x-axis of the bar chart and the percentage of Ag85B, TB10.4 or Ag85B-TB10.4 (H4) specific CD4
+ T cells
expressing any combination of cytokines is given for each immunization group. The antigen used for in vitro stimulation of the PBMC’s is indicated. No
responses were seen in the CD8
+ T cell subset. (E) The mean fluorescence intensity (MFI) of IFN-c in the subpopulations expressing this cytokine from
animals vaccinated with either 0.5 mgH 4o r5mg H4. Results are representative of two independent experiments.
doi:10.1371/journal.pone.0005930.g003
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down to 0.005 mg( 61000 fold reduction) led to a stronger immune
response directed to both vaccine components (Fig. 1 and 2). In
previous work we have shown that the optimal vaccination dose
for the Ag85B-ESAT-6/CAF01 antigen was approximately 10 mg,
but also for this antigen there was an inhibition of the cellular
immune response at higher doses [16]. When analyzing the
expression of IFN-c, IL-2, and TNF-a we found that Ag85B-
TB10.4/IC31H vaccination induced two major CD4 T cell
populations, one co-expressing IFN-c, IL-2, and TNF-a, and
another expressing IL-2 and TNF-a (Fig. 3). By decreasing the
antigen dose we observed a selective increase in the CD4 T cell
population expressing IFN-c, IL-2, and TNF-a. In agreement with
the IFN-c secretion measured by ELISA it was the lowest dose of
Ag85B-TB10.4 (0.5 mg) that induced the highest number of
specific T cells (Fig. 2), in particular polyfunctional T cells (Fig. 3),
which showed an increased production of IFN-c compared to the
T cells from animals vaccinated with the higher antigen dose of
5 mg (Fig. 3E). The highly potentiated immune response induced
in the low dose vaccinated mice correlated with increased
protection against infection with virulent M.tb (Fig. 4). These
results are in agreement with a number of recent studies on various
pathogens in different animal models which have shown that not
only the magnitude, but also the quality, of the T cell response
appear to have significant impact on the establishment of
protective memory. Hence, measuring a single factor such as
IFN-c production or frequency may not reflect the full functional
potential of Th1 cells, and the ability of memory T cells to co-
express multiple cytokines seems to be important for endowing
these cells with superior recall responses [14,17]. Furthermore,
polyfunctional CD4 T cells are characteristic of the response in
HIV-controllers and display an inverse correlation with viral load,
whereas non-controllers elicit responses dominated by IFN-c
single positive CD4 T cells [18]. In mice, vaccine-induced
polyfunctional CD4 T cells have been shown to correlate with
protection against Leishmania major infection as the degree of
protection against Leishmania major infection in mice correlated
with the frequency of CD4 T cells simultaneously producing IFN-
c, IL-2 and TNF-a. The mechanisms by which such polyfunc-
tional, triple-positive cells exert their function may be manifold.
IFN-c is clearly indispensable for resistance to mycobacterial and
other intracellular infections [19], and TNF-a is on its own an
effector cytokine, which can synergise with IFN-c to eliminate
intracellular pathogens [20,21]. Regarding IFN-c, it is interesting
that on a per cell basis, the T cells from animals vaccinated with
the low vaccine dose produced more IFN-c per cell than T cells
from animals vaccinated with the high dose. Moreover, the
polyfunctional T cells in both the vaccine groups were more
efficient producers of IFN-c than the double (IFN-c/TNF-a)o r
single-positive (IFN-c) CD4 T cells (Fig. 3E, and data not shown).
This finding is in accordance with a recent report from Leishmania
vaccination studies in mice that showed that polyfunctional
effector cells were unique in their capacity to produce high
amounts of IFN-c [14]. In addition, human studies have also
showed that triple-positive antiviral T cells expressed the highest
levels of cytokines per cell, while the single positive T cells
expressed the lowest [18,22,23]. Thus, polyfunctionel cells may be
superior both in terms of establishing immunological memory, as
well as in producing high amounts of cytokines.
Previous studies have shown that vaccination with 5 mgo f
Ag85B-TB10.4 in cationic liposomes was as protective as BCG in
a mouse TB animal model [8] unlike 5 mg Ag85B-TB10.4 in
IC31H (Fig. 4). Moreover, the dose of 5 mg of Ag85B-ESAT-6 in
IC31H was as protective as BCG in a mouse TB model [10]. These
differences suggest that the Ag85B-TB10.4 and Ag85B-ESAT-6
molecules, when combined with the adjuvants IC31H or cationic
liposomes, differ in their immunogenicity and dose/response
relationship. Our findings highlight the importance of optimizing
Figure 4. Protective efficacy of different doses of Ag85B-
TB10.4 in IC31H. In two independent experiments (A and B) groups of
mice were vaccinated with three different doses of H4 formulated in
IC31H and compared to saline and BCG vaccinated controls. All groups
were challenged by the aerosol route with virulent M.tb ten weeks after
the first vaccination. Six weeks post-challenge, all mice were killed and
the bacterial burden (CFU) was measured in the lung. In both
experiments data are presented as mean values from six animals per
group and standard errors of the means are indicated by bars. Statistical
comparison among the vaccination groups were done by one-way
ANOVA and Tukey’s post test. Significant differences are shown. ***:
p,0.001, *: p,0.05.
doi:10.1371/journal.pone.0005930.g004
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the optimal efficacy of the vaccine clearly depends both on the
dose of the antigen and the adjuvant used. Our results indicated
that increasing the antigen dose did not favor a Th2 response, as it
did not lead to increased production of antibodies normally
associated with a Th2 response (data not shown). It could be
suggested that using a high a dose of a highly immunogenic
antigen, such as the one used in this study, may not sufficiently
allow for generation of protective memory T cells, but will instead
lead to short lived terminally differentiated effector T cells, a
subset that would already be contracted or show reduced cytokine
response, and therefore not be detectable, at the time point for the
immunological evaluation. Confirming our results obtained with
the mouse TB model, we showed that the guinea pig model was
also very sensitive to the dose of antigen used for vaccination. Also
in this model, small doses (1 mg Ag85B-TB10.4) showed some
protective efficacy whereas increasing the optimal dose 2.5 fold
(from 20 to 50 mg) reduced the protection to a level not different
from that seen in non-vaccinated animals. These results thus
confirmed that 1) small changes in the dose of antigen can
significantly affect the efficacy of the vaccine, 2) increasing the
vaccine dose beyond a specific threshold decreases the protective
efficacy, 3) different animal models have different optimal doses
(that probably depend on both the antigen and the adjuvant), and
4) the optimal dose of Ag85B-TB10.4 in IC31H does induce
significant protection also in the guinea pig TB model.
Taken together, a more comprehensive understanding of the
full functional capacity of effector and memory T cell responses is
needed, which may have important implications for vaccine design
and development. One of the important success criterion for any
vaccine, is the formation of a reservoir of memory cells of both
adequate size and quality to maintain efficient immune surveil-
lance for prolonged periods. Consequently, for evaluating
vaccines, memory responses should be examined in terms of
frequency, phenotype, quality and persistence of the memory T
cells induced, as all of these factors are anticipated to contribute to
a successful vaccination regimen. Importantly, our study shows
that the dose of the vaccine antigen can dramatically affect several
of these important parameters, and titration of the antigen dose
should be a high priority in all vaccine testing programs, in animal
models as well as in the initial clinical trials. Finally, in terms of
vaccine efficacy we have shown that the Ag85B-TB10.4/IC31H
vaccine is a very a promising TB vaccine candidate. Clinical
testing of a range of different doses of Ag85B-TB10.4 in IC31H
was recently initiated.
Materials and Methods
Ethics Statement
The handling of mice were conducted in accordance with the
regulations set forward by the Danish Ministry of Justice and
animal protection committees by Danish Animal Experiments
Figure 5. Kaplan-Meier plot of different doses of Ag85B-TB10.4 in the guinea pig TB model. (A and B). Groups of 15 animals per group
were vaccinated three times with Ag85B-TB10.4 in IC31H or with IC31H alone (as a negative control). For antigen dose we used from 0.1 mgt o5 0mg.
10 weeks after the last vaccination the animals were infected via the aerosol route with virulent M. tuberculosis, and monitored for weight loss post
infection. B. Selected groups from the same experiment.
doi:10.1371/journal.pone.0005930.g005
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Directive 86/609 and the U.S. Association for Laboratory Animal
Care recommendations for the care and use of laboratory animals.
All guinea pig experimental procedures were approved by the
Colorado State University Institutional Animal Care and Use
Committee.
Animals
Studies were performed with 6–8 week-old female CB6F1
(BALB/c6C57BL/6) mice from Harland Netherlands. Infected
animals were housed in cages contained within laminar flow safety
enclosures in a BSL-3 facility. All mice were fed radiation sterilized
2016 Global Rodent Maintenance diet (Harlan, Scandinavia) and
water ad libitum. All animals were allowed a one-week rest before
initiation of the experiments. Out-bred Hartley guinea pigs
(Charles River Laboratories, Wilmington MA) were infected and
housed in cages contained within a BL-3 laminar flow safety
enclosure. Guinea pigs were weighed weekly and were euthanized
based on weight loss, increased respiratory rate (laboured/heavy
breathing) and general behaviour and appearance.
Bacteria
Mycobacterium tuberculosis Erdman were grown at 37uCo n
Lo ¨wenstein-Jensen medium or in suspension in Sauton medium
enriched with 0.5% sodium pyruvate and 0.5% glucose. M.
tuberculosis H37Rv (TMC#102) for guinea pig infection studies was
grown in Proskaur & Beck medium as described previously [24].
Vaccination
Mice were vaccinated three times at 2-week intervals subcuta-
neously on the back with experimental vaccines containing 0.005,
0.05, 0.5, 5 or 15 mg of Ag85B-TB10.4 (H4)/dose, emulsified in
IC31H in a total volume of 0.2 ml/dose. The adjuvant
IC31Hconsists of a mixture of the peptide KLK (NH2-
KLKL5KLK-COOH) and the oligodeoxynucleotide ODN1a
(oligo-(dIdC)13) provided by Intercell. Doses were 100 nmol
peptide and 4 nmol oligonucleotide. All vaccines were formulated
using 10 mM Tris-HCL/270 mM sorbitol buffer (pH 7.9) as
previously described [12] to obtain a final volume of 0.2 ml/
mouse. At the time of the first subunit vaccination, one group of
mice received a single dose of BCG Danish 1331 (2.5610
5 CFU)
injected subcutaneously at the base of the tail and one group
received a saline injection. All groups of mice were challenged 10
weeks after the first vaccination.
Experimental infections
When challenged by the aerosol route, the mice were infected
with approximately 50 CFU of M. tuberculosis Erdman/mouse.
These mice were sacrificed 6 weeks after challenge. Numbers of
bacteria in the spleen or lung were determined by serial threefold
dilutions of individual whole-organ homogenates in duplicate on
7H11 medium. Organs from the BCG-vaccinated animals were
grown on medium supplemented with 2 mg of 2-thiophene-
carboxylic acid hydrazide (TCH)/ml to selectively inhibit the
growth of the residual BCG bacteria in the test organs. Colonies
were counted after 2 to 3 weeks of incubation at 37uC. Bacterial
burden in the lungs was expressed as log10 coloni forming units
(CFU).
Lymphocyte cultures
Lymphocytes from spleens were obtained as described previ-
ously [25]. Briefly, peripheral blood mononuclear cells (PBMCs)
were purified on a density gradient of mammal lympholyteH cell
separation media (Cedarlane Laboratories Inc., Canada). PBMC
containing layers was carefully transferred to a new tube, and two
washing procedures using RPMI was performed before cells were
counted. Cells pooled from five mice in each experiment were
cultured in microtiter wells (96-well plates; Nunc, Roskilde,
Denmark) containing 2610
5 cells in a volume of 200 ml of RPMI
1640 supplemented with 5610
25 M 2-mercaptoethanol, 1%
penicillin-streptomycin, 1 mM glutamine, and 5% (vol/vol) fetal
calf serum. Based on previous dose-response investigations, the
mycobacterial antigens were all used at 1 mg/ml. All preparations
were tested in cell cultures and found to be nontoxic at the
concentrations used in the present study. Supernatants were
harvested from cultures after 72h of incubation for the
investigation of IFN-c.
IFN-c enzyme-linked immunosorbent assay (ELISA)
Microtiter plates (96 wells; Maxisorb; Nunc) were coated with
monoclonal hamster anti-murine IFN-c (Genzyme, Cambridge,
Mass.) in PBS at 4uC. Free binding sites were blocked with 1%
(wt/vol) bovine serum albumin-0.05% Tween 20. Culture
supernatants were tested in triplicate, and IFN-c was detected
with a biotin-labelled rat anti-murine monoclonal antibody (clone
XMG1.2; Pharmingen, San Diego, CA). Recombinant IFN-c
(Pharmingen, San Diego, CA) was used as a standard.
Flow cytometry analysis of lymphocytes
Intracellular cytokine staining procedure: Cells from blood,
spleen or lungs of mice were stimulated for 1–2 h with 2 mg/ml Ag
at 37uC and subsequently incubated for 5 h at 37uC with 10 mg/
ml brefeldin A (Sigma-Aldrich, Denmark) at 37uC. Fc receptors
were blocked with 0.5 ı `g/ml anti-CD16/CD32 mAb (BD
Pharmingen, USA) for 10 minutes, whereafter the cells were
washed in FACS buffer (PBS containing 0.1% sodium azide and
1% FCS) before staining with a combination of the following rat
anti-mouse antibodies PE-Cy7-, PerCP-Cy5.5-anti-CD8a ´ (53–6.7,
RM4-5), APC-Cy7-anti-CD4 (GKI.5) (Pharmingen, San Diego,
USA). Cells were washed with FACS buffer before fixation and
permeabilization using the BD Cytofix/Cytoperm
TM (BD, San
Diego, CA, USA) according to the manufacturer’s protocol before
intracellular staining with PE-, PE-Cy7, APC-Anti-IFN-a ˜
(XMG1.2), PE-anti-TNFa, and/or PE-, APC-anti-IL-2 (JES6-
5H4). After washing, cells were resuspended in formaldehyde
solution 4% (w/v) pH 7.0 (Bie & Berntsen, Denmark) and samples
were analyzed on a six-color BD FACSCanto flow cytometer (BD
Biosciences, USA). Data analysis was done with FACSDiva
Software (Becton-Dickinson, San Diego, CA, USA) and Flowjo
Software ( Tree Star, Asland, OR, USA).
IFN-c ELISPOT
96-well microtiter plates (MAHA S45 10 cellulose ester,
Millipore) were coated with 4 mg/ml monoclonal rat anti-murine
IFN-c (clone R4-6A2; BD Pharmingen). Free binding sites were
blocked with RMPI 1640 supplemented as described above for
lymphocyte cul-tures. After 48 hrs of incubation with 2 mg/ml Ag
at 37uC IFN-c was detected with 1.25 m/ml biotin labeled rat anti-
murine Ab (clone XMG1.2; BD Pharmingen) and 0.5 mg/ml al-
kaline phosphatase-conjugated streptavidin (Jackson ImmunoR-
esearch Laboratories Europe). The enzyme reaction was devel-
oped with SIGMA FAST
TM BCIP/NBT (5-Bromo-4-chloro-3-
indolyl phosphate/Nitro blue tetrazolium) (Sigma-Aldrich, Den-
mark) and stopped by washing the plates with ddH2O. ELISPOT
plates were counted using an AID plate reader (Autoimmun
Diagnostika, Strassberg, Germany) and AID ELISPOT 3.0c
H4/IC31 Protects against M.tb
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units (SFU)/10
6 spleen cells.
Statistical methods
The data obtained were tested by analysis of variance.
Differences between means were assessed for statistical significance
by Tukey’s test. A P value of ,0.05 was considered significant.
The Log Rank tested was used to analyze guinea pig survival data.
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